LANCE: Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy
Sponsor: |
Conquer Cancer Foundation of the American Society of Clinical Oncology and DOD |
Enrolling: |
Female Patients Only |
IRB Number: |
AAAT3353 |
Contact: |
Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu |
The goal of this clinical research study is to compare the outcomes of minimally invasive surgery (the investigational surgery) to laparotomy (the current standard of care) in women with Epithelial Ovarian Cancer (EOC) who receive chemotherapy before and after surgery. Researchers want to learn if one surgery can prevent the disease from returning for longer and/or improve your quality of life after surgery. Both the minimally invasive surgery and laparotomy procedures in this study are performed using FDA-approved and commercially available methods. It is considered investigational to compare the outcomes of these methods when used to treat advanced EOC in women who have responded to neoadjuvant chemotherapy.
Investigator
Jason Wright, MD
Have you been diagnosed with stage 3 or 4 ovarian, fallopian tube or primary peritoneal cancer? |
Yes |
No |
Have you received chemotherapy? |
Yes |
No |